In the News

The company’s 4Sight project pioneers the creation of a specialised visualiser to allow its research scientists to view, understand and interrogate the complex, multidimensional molecular shape data of drug molecules. Having measured these shapes using the company’s proprietary Conformetrix technology, this “4D molecular data” can then be visualised and manipulated to inspire the design of drug molecules in new and innovative ways. Working from both a desktop environment and within a VR space, the visualiser also facilitates simultaneous collaboration with multiple stakeholders across various sites.

“4Sight allows users to see the results of an experiment and a view of drug molecules in ways that have never before been possible”, as C4X’s Chief Scientific Officer Craig Fox explains.

Clive Dix, chief executive of C4X Discovery Holdings plc, (LON:C4XD) brings Proactive up to speed on developments with the firm's portfolio of drug candidates.

They've recently presented some pre-clinical data at a leading industry conference which they say strengthens the evidence base backing the potential of the anti-addiction drug Orexin-1. It's being developed to target the craving process and therefore is expected to be used across a broad range of substance disorders. The latest study assessed nicotine self-administration and cue-induced reinstatement; the latter is where strong cravings are triggered by an object or ritual closely associated with taking an addictive substance.

Wednesday, 08 November 2017 - Movers and Shakers in BioBusiness 2017

In the News Bhavna Hunjan wins a Rising Star award for Movers and Shakers in BioBusiness 2017

Bhavna is building the commercial team having, together with the CEO, re-shaped the company’s strategy, and supported the recent £7 million raise. Bhavna is establishing collaborations with international organisations to harness the best drug discovery capabilities for the development of new treatments. She is also developing alliances with UK non-profit organisations to maximise the impact of intellectual value developed by academics and in-house at C4X.

Monday, 06 November 2017 - Evening Standard

In the News Market minnows: C4X Discovery

Casting the net for tiddlers who want to be whales.

Friday, 07 July 2017 - Pharma Letters

In the News In conversation with Dr Clive Dix

The Pharma Letter's news editor, Katie Osborne, talks to Dr Clive Dix, chief executive of British drug discovery and development company, C4X Discovery, about his career, his top tips for success, Brexit and more.

The company has acquired “a virtual library of over a billion molecules”, which should give the company a boost when it starts new discovery programmes.

According to Dr Clive Dix, the chief executive officer of C4X, the newly acquired software is “all about optimising those molecules that we find by using our other technologies”.

Dr Dix told Proactive Investors: “Everything we do is aimed at reducing the time and the cost of getting to the clinical trial and then … with the molecules we have being of higher quality, they’ll be more likely to be successful in the trials.”
The company will be starting new projects on a regular basis and when the time is right will decide on a case-by-case basis whether to bring in a partner or take the drugs to clinical trial independently.

Taxonomy 3 analyses publicly available databases to identify previously unknown linkages between genes and diseases.

C4X Discovery Holdings (LON:C4XD) chief executive Clive Dix said the company had studied rheumatoid arthritis and Parkinson's disease data. "What we have found are genes that are highly associated with these diseases."